Home » Clinical Trials » Location » France
Toulose, France Clinical Trials
A listing of Toulose, France clinical trials actively recruiting patients volunteers.
Found (527) clinical trials
Blood Pressure Target in Acute Stroke to Reduce hemorrhaGe After Endovascular Therapy
Patients will be followed for 3 months: inclusion after reperfusion: clinical evaluation with NIHSS (National Institute of Health Stroke Score) score, measurement of blood pressure. within 24 hours after reperfusion: blood pressure measurements at 24 hours: measurement of blood pressure (T0 + 24 h and evaluation of the NIHSS score. ...
3.84 miles
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
The purpose of this study is to determine whether nivolumab plus ipilimumab or nivolumab alone is effective and safe in the treatment of solid tumors with High Tumor Mutational Burden (TMB-H)
3.84 miles
Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
Part A (dose-optimization)- to determine the recommended phase 2 dose (RP2D) taking into account dose-limiting toxicity (DLT/s) in Cycle 1, overall safety/tolerability and pharmacokinetic (PK), by optimizing doses of Debio 1143 when combined with the standard dose of nivolumab, as well as treatment compliance in participants with advanced solid malignancies ...
3.84 miles
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Marginal zone lymphomas (MZL) represent a group of indolent B-cell lymphomas that arises from marginal zone B-cells in extranodal tissues, such as spleen and mucosa associated lymphoid tissues, and more rarely also in nodal tissues. MZL comprises 5 to 17% of all non-Hodgkin lymphomas (NHL) in adults. The 2016 World ...
3.84 miles
The European Paediatric Network for Haemophilia Management ( PedNet Registry)
Design: Prospective observational cohort Population Patients with haemophilia A and B with FVIII/IX levels of <1 to 25% born between 1-1-2000 and 1-1-2020. Intervention No intervention; only documentation of patient characteristics and parameters of routine patient care and outcome Main outcome parameters: Outcome: clinically relevant inhibitor development, bleeding pattern and ...
4.07 miles
Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain
DISCOGEL is on the market since 2007. About 20,000 kits were sold to date (October 2017). The device re-obtained its CE mark in 2017. A clinical evaluation was performed by bibliographic route in 2016. Clinical data on more than 600 patients treated by DISCOGEL were analyzed. These data should be ...
4.14 miles
Efficacy of Additional Osteotomies to Correct Hallux Valgus
Deviation of the big toe in valgus at the level of the first metatarsophalangeal joint is called Hallux Valgus. In case of significant pain especially due to a conflict with the shoes, surgery could be indicated. Angle between the first metatarsal (M1) and the first phalangeal (P1) is named Hallux ...
5.16 miles
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
Non Small Cell Lung Cancer (NSCLC) remains the leading cause of death by cancer in the world. Because of the increase in lung cancer incidence with age and the increase of life expectancy, about half of the patients are patients aged 70 or older. Several clinical trials have shown the ...
5.25 miles
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
In the majority of European countries, the primary management of chronic heart failure patients is performed by General Practitioners in collaboration with cardiologists (specialists). Previous studies have shown that many patients suffering from CHF do not receive optimal pharmacological and/or device treatment for their disease. An increase in natriuretic peptides ...
5.31 miles
Study of the Practice of Debiri in France
Colorectal cancer (CRC) is the third most common cancer in men and the second in women (1.23 million cases in 2008, 608700 deaths) 40 to 50% of patients developed hepatic, synchronous or metachronous metastases. In 10 to 15% of cases, these metastases are operable initially, and a perioperative chemotherapy of ...
6.65 miles